IMUGENE LIMITED — AGM Information 2009

Nov 26, 2009

==> picture [720 x 182] intentionally omitted <==

IMUGENE LIMITED Advanced Vaccine Technologies Disease control in pigs and poultry

Annual General Meeting 27 November 2009

==> picture [720 x 182] intentionally omitted <==

----- Start of picture text -----

Today’s meeting
----- End of picture text -----

• 10.30am

• Address from Chairman - Mr Graham Dowland

– Presentation from CEO - Dr Warwick Lamb

• Your questions

• 11.00 am

• Formal agenda

  • Resolutions

This document has been prepared by Imugene Limited (“Imugene”) in connection with providing an overview to interested analysts and investors.

This presentation is being provided for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of Imugene. This presentation is thus by its nature limited in scope and is not intended to provide all available information regarding Imugene. This presentation is not intended as an offer, invitation, solicitation, or recommendation with respect to the purchase or sale of any securities. This presentation should not be relied upon as a representation of any matter that a potential investor should consider in evaluating Imugene.

Imugene and its affiliates, subsidiaries, directors, agents, officers, advisers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained in this presentation, and they do not accept any liability or responsibility for any statement made in, or omitted from, this presentation. Imugene accepts no obligation to correct or update anything in this presentation.

No responsibility or liability is accepted and any and all responsibility and liability is expressly disclaimed by Imugene and its affiliates, subsidiaries, directors, agents, officers, advisers and employees for any errors, misstatements, misrepresentations in or omissions from this presentation.

Any statements, estimates, forecasts or projections with respect to the future performance of Imugene and/or its subsidiaries contained in this presentation are based on subjective assumptions made by Imugene's management and about circumstances and events that have not yet taken place. Such statements, estimates, forecasts and projections involve significant elements of subjective judgement and analysis which, whilst reasonably formulated, cannot be guaranteed to occur. Accordingly, no representations are made by Imugene or its affiliates, subsidiaries, directors, officers, agents, advisers or employees as to the accuracy of such information; such statements, estimates, forecasts and projections should not be relied upon as indicative of future value or as a guarantee of value or future results; and there can be no assurance that the projected results will be achieved.

Prospective investors should make their own independent evaluation of an investment in Imugene.

Nothing in this presentation should be construed as financial product advice, whether personal or general, for the purposes of section 766B of the Corporations Act 2001 (Cth). This presentation consists purely of factual information and does not involve or imply a recommendation or a

==> picture [720 x 182] intentionally omitted <==

Chairman’s Address

==> picture [720 x 182] intentionally omitted <==

CEO Presentation

Signed on 31 December 2008

Year 1 focus: technology transfer & evaluation of manufacturing options Sublicenced vaccines: PRRS & PPE

Imugene

Merial

• Technology transfer

• Fund product development

• Provide vaccines for trials

• Design & perform all trials

• Expand product pipeline

• Construct new vaccines

• Develop commercial scale manufacturing process

• Manage patent position

• Modify existing vaccines if

• All regulatory work

• Maximise product range from

• Stage Pigs

• Passed • PRRS – Porcine Reproductive & commercial Respiratory Syndrome vaccine proof of concept • Classical Swine Fever vaccine

Passed • Swine influenza vaccines for H1N1 laboratory and H3N2 strains testing

In laboratory	•	Porcine Circovirus vaccine
development	•	Porcine Parvovirus vaccine

Poultry

• PPE - Poultry Productivity Enhancer proven to boost growth and weight

• • H5N1 avian influenza vaccine

• • Coccidiosis preventative vaccine

• • H7 and H9 avian influenza vaccine

• • Chicken Anaemia Virus • Infectious Bursal Disease vaccine

• Infectious

Commercial advantages

• Cost effective to manufacture & administer via water, feed, aerosol, or injection

• High efficacy at an early age

• Deliver only key genetic information

• Can deliver multiple genes

• Do not cause disease or create

• meat residues so are safe for

human consumption

Market

• Global market - US$3 billion + per year

• Biological products ↑

• Antibiotics ↓

• Poultry Productivity Enhancer

  • 48 billion broilers produced each year

• PRRS

  • losses of up to US$1 billion

• Do not genetically modify the

• Renewed focus on market engagement

– Engagement of Buchan Consulting

• Perception study

• Biannual shareholder briefings

• Regular analyst briefings, focused on expanding support base

• Refresh of website

• Media relations

• Technology transferred to Merial

• Swine influenza - completed laboratory construction & testing of vaccines for H1N1 and H3N2 strains

• Expansion of patent portfolio

• Achieved positive operating annual cash flow of AU$959,000

Imugene Limited ASX: IMU

Dr Warwick Lamb Managing Director + 61 8 9440 2660 wlamb@imugene.com